Regenxbio Inc (NAS:RGNX)
$ 10 0.08 (0.81%) Market Cap: 495.45 Mil Enterprise Value: 320.09 Mil PE Ratio: 0 PB Ratio: 1.64 GF Score: 65/100

Regenxbio Inc RGX-314 Update Call Transcript

Aug 04, 2020 / 12:30PM GMT
Release Date Price: $33.74 (-1.72%)
Operator

Good morning, and welcome to the REGENXBIO conference call to provide updates from the RGX-314 wet AMD program. (Operator Instructions) As a reminder, this conference call is being recorded. (Operator Instructions) I would now like to turn the conference over to Mr. Patrick Christmas, Chief Legal Officer for REGENXBIO. You may begin.

Patrick J. Christmas
REGENXBIO Inc. - Chief Legal Officer

Good morning, and thank you for joining us today. Earlier this morning, REGENXBIO provided an update via press release, which is available on our website at www.regenxbio.com. We will also be reviewing slides during this call, which you can access via the Investors Section of our website.

Today's conference call will include forward-looking statements regarding our clinical development of RGX-314, in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasts and can be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot